Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 268-776-5 | CAS number: 68140-14-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 20 Feb 2007 - 28 Feb 2007
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- This study has been performed according to OECD and/or EC guidelines and according to GLP principles.
Cross-reference
- Reason / purpose for cross-reference:
- read-across source
Reference
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Justification for type of information:
- It is considered appropriate to address the data requirements for DTO_DETA by read-across to the available studies on the main components of DTO_DETA: AAI_DETA and Rosin.
DTO_DETA contains comparatively lower levels of imidazolines and higher levels of resin acids than AAI_DETA and therefore consideration of data for resin acids is also considered necessary. The main resin acid in DTO_DETA is abietic acid, but abietic acid derivatives and other acids, such as pimaric acid, are also found in notable quantities, and the resin acids collectively are known as ‘rosin’. DTO_DETA contains up to 25% unreacted rosin, and taking into account the compositional information available for the rosin in DTO_DETA and Rosin (CAS# 8050-09-07, EC# 232-475-7), the latter was considered appropriate for read-across to DTO_DETA.
An LLNA (OECD 429) is available for AAI_DETA (CIT, 2007), the main component in DTO_DETA. Based on the results of this study, AAI_DETA was classified as a Category 1A Skin Sensitiser. A guideline guinea pig maximisation test (NOTOX, 2010) is also available with the read across substance AAI_DETA; this study confirms the result obtained in the LLNA. As AAI_DETA is a major component in DTO_DETA, read across to the AAI_DETA dataset is justified and presents the worst case approach. Several negative studies (LLNAs, guinea pig maximisation tests and a Buehler assay) conducted with Rosins are provided as supporting information; these studies are provided to demonstrate that the Rosin component of DTO_DETA will not significantly increase the hazard profile of DTO_DETA with respect to skin sensitisation. A positive study conducted with Wood Rosin (CTL, 1997g) is available and is included in the dossier for information purposes, however the study was disregarded because the test substance sample was heavily oxidised and degraded. - Reason / purpose for cross-reference:
- read-across source
- Key result
- Parameter:
- EC3
- Value:
- 0.3
- Parameter:
- SI
- Value:
- 1
- Test group / Remarks:
- 0.05% test item
- Parameter:
- SI
- Value:
- 1.88
- Test group / Remarks:
- 0.1% test item
- Parameter:
- SI
- Value:
- 1.67
- Test group / Remarks:
- 0.25% test item
- Parameter:
- SI
- Value:
- 5.91
- Test group / Remarks:
- 0.5% test item
- Parameter:
- SI
- Value:
- 18.65
- Test group / Remarks:
- 1% test item
- Interpretation of results:
- Category 1A (indication of significant skin sensitising potential) based on GHS criteria
- Conclusions:
- Based on the results of the read across study, DTO_DETA is considered to be skin sensitiser. Classification according to CLP is required (Cat 1A Skin Sensitiser).
- Executive summary:
A guideline (OECD 429) LLNA (CIT, 2007) is available for the read across (source) substance, AAI_DETA. Read across from AAI_DETA to the target, DTO_DETA, is considered appropriate because AAI_DETA is a major component of DTO_DETA. AAI_DETA was found to be to a strong skin sensitiser. Therefore, based on the results of this study, DTO_DETA should be classified as a Category 1A Skin Sensitiser according to the CLP Regulation. Several studies (LLNAs, guinea pig maximisation tests and a Buehler assay) are available for the Rosin data set, and are presented as supporting read across information to demonstrate that the Rosin component of DTO_DETA will not significantly increase the hazard profile of DTO_DETA with respect to skin sensitisation.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 007
- Report date:
- 2007
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- mouse local lymph node assay (LLNA)
Test material
- Reference substance name:
- Fatty acids, C18 unsat, reaction products with diethylenetriamine
- EC Number:
- 629-715-1
- Cas Number:
- 1226892-43-8
- Molecular formula:
- UVCB substance - not applicable
- IUPAC Name:
- Fatty acids, C18 unsat, reaction products with diethylenetriamine
Constituent 1
- Specific details on test material used for the study:
- Certificate of analysis included in report.
description: Fatty acids, C12-18 and C18 insaturated, reaction products with diethylenetriamine.
CASno:: 91001-82-0
Purity: 100%
Ration Imidazoline/amide: 50.24% imidazoline
Origin: CECA - Feuchy
Batch: pilote du 27/07/06
Arkema filing no: GRL 0055/06
Aspect: thick clear brown liquid
density: approx. 950 kg/m3 at 25°C
Expiry date: July 2007
In vivo test system
Test animals
- Species:
- mouse
- Strain:
- CBA
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Janvier, Le Genest-Saint-Isle, France
- Age at study initiation: approximately 9 weeks
- Weight at study initiation: mean body weight ± standard deviation of 20.9 ± 1.0 g.
- Housing: individually in disposable crystal polystyrene cages (22.00 cm x 8.50 cm x 8.00 cm). Each cage contained autoclaved sawdust (SICSA, Alfortville, France)
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period:
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2°C
- Humidity (%): 30 to 70%,
- Air changes (per hr): 12 cycles/hour of filtered, non-recycled air.
- Photoperiod (hrs dark / hrs light): 12 h/12 h,
IN-LIFE DATES: From: 20 Feb 2007 To: 28 Feb 2007
Study design: in vivo (LLNA)
- Vehicle:
- acetone/olive oil (4:1 v/v)
- Concentration:
- 0, 0.05, 0.1, 0.25 and 1 % (v/v)
- No. of animals per dose:
- 4 females/dose
- Details on study design:
- RANGE FINDING TESTS:
- Irritation: Erythema and crusts were noted on ears of all animals given the concentrations ≥ 2.5%. A significant increase in ear thickness was recorded at concentrations ≥ 2.5%, showing the irritant potential of the test item at these concentrations. The highest concentration retained for the main test was therefore 1%.
MAIN STUDY
ANIMAL ASSIGNMENT AND TREATMENT
- Name of test method:
- Criteria used to consider a positive response:
TREATMENT PREPARATION AND ADMINISTRATION: - Positive control substance(s):
- hexyl cinnamic aldehyde (CAS No 101-86-0)
- Statistics:
- SI = dpm of treated group / dpm of control group
skin sensitizer when the SI for a dose group is ≥ 3.
EC3 derived by linear interpolation of points on the dose-response curve, immediately above and below the 3-fold threshold.
Results and discussion
- Positive control results:
- HCA 25%, SI = 14.38. The study was therefore considered valid.
In vivo (LLNA)
Resultsopen allclose all
- Key result
- Parameter:
- EC3
- Value:
- 0.3
- Parameter:
- SI
- Value:
- 1
- Test group / Remarks:
- 0.05% test item
- Parameter:
- SI
- Value:
- 1.88
- Test group / Remarks:
- 0.1% test item
- Parameter:
- SI
- Value:
- 1.67
- Test group / Remarks:
- 0.25% test item
- Parameter:
- SI
- Value:
- 5.91
- Test group / Remarks:
- 0.5% test item
- Parameter:
- SI
- Value:
- 18.65
- Test group / Remarks:
- 1% test item
Any other information on results incl. tables
No mortality and no clinical signs were observed during the study.
The body weight change of treated animals was similar to that of control animals.
Local irritation:
A dryness of the skin of the ears was noted on day 6 in animals given the concentrations of 0.5 and 1%.
Increases in ear thickness were noted at concentrations of 0.5% (19.19% increase) and 1% (30.10% increase).
Proliferation assay:
The quantity of cells obtained in each group was satisfactory and the cellularity correlated with incorporation of 3H-TdR. The cell viability was higher than 70% in each group.
In the positive control group given HCA at the concentration of 25%, a moderate increase in cellularity and a stimulation index exceeding the threshold value of 3 (SI = 14.38) were noted. The study was therefore considered valid.
A dose-related increase in the SI was recorded and the threshold positive value of 3 was exceeded at 0.5%.
In the absence of an excessive local irritation at the concentration of 0.5% (increase in ear thickness < 30%), the significant lymphoproliferative response observed was attributed to delayed contact hypersensitivity.
The EC3 value for the test item IMIDAZOLINE 4900 is equal to 0.3%.
Study results
Group |
Treatment concentration |
Cell count |
viable % |
amount of cells |
Cellularity index |
Number of nodes per group |
dpm per group |
dpm per node |
Stimulation Index (SI) |
Increase in ear thickness (% between day 1 and day 6) |
Irritation level |
EC3 value (%) |
|
viable |
dead |
||||||||||||
1 |
Vehicle |
42 |
8 |
84.00 |
4.20 |
|
8 |
375.97 |
47.00 |
|
1.98 |
|
|
2 |
Test Item 0.05% |
46 |
9 |
83.64 |
4.60 |
1.10 |
8 |
375.95 |
47.12 |
1.00 |
0.98 |
I |
|
3 |
Test Item 0.1% |
66 |
10 |
86.84 |
6.60 |
1.57 |
8 |
707.84 |
88.48 |
1.88 |
1.00 |
I |
0.3 |
4 |
Test Item 0.25% |
67 |
8 |
89.33 |
6.70 |
1.60 |
8 |
629.60 |
78.70 |
1.67 |
8.16 |
I |
|
5 |
Test Item 0.5% |
154 |
40 |
79.38 |
15.40 |
3.67 |
8 |
2221.13 |
277.64 |
5.91 |
19.19 |
II |
|
6 |
Test Item |
258 |
52 |
83.23 |
25.80 |
6.14 |
8 |
7012.20 |
876.53 |
18.65 |
30.10 |
III |
|
7 |
HCA |
250 |
32 |
88.65 |
25.00 |
5.95 |
8 |
5406.58 |
675.82 |
14.38 |
|
|
|
Applicant's summary and conclusion
- Interpretation of results:
- Category 1A (indication of significant skin sensitising potential) based on GHS criteria
- Conclusions:
- Test item should be considered as a strong sensitizer. CLP skin sensitiser Cat. 1A
- Executive summary:
The aim of this study was to evaluate the potential of the test item IMIDAZOLINE 4900 (batch No. pilote du 27/07/06) to induce delayed contact hypersensitivity using the murine Local Lymph Node Assay (LLNA). Evaluation of local irritation was also carried out in parallel.
This study was conducted in compliance with the principles of Good Laboratory Practice Regulations.
Methods
A preliminary test was first performed in order to define the concentrations of test item to be used in the main test.
In the main test, twenty-eight female CBA/J mice were allocated to seven groups:
- five treated groups of four animals receiving the test item IMIDAZOLINE 4900 at the concentration of 0.05, 0.1, 0.25, 0.5 or 1%,
- one negative control group of four animals receiving the vehicle (mixture acetone/olive oil (4/1, v/v)),
- one positive control group of four animals receiving the reference item,α-hexylcinnamaldehyde (HCA), a moderate sensitizer, at the concentration of 25%.
During the induction phase, the test item, vehicle or reference item was applied over the ears (25 μL per ear) for 3 consecutive days (days 1, 2 and 3). After 2 days of resting, the proliferation of lymphocytes in the lymph node draining the application site was measured by incorporation of tritiated methyl thymidine (day 6). The obtained values were used to calculate stimulation indices (SI).
The irritant potential of the test item was assessed in parallel by measurement of ear thickness on days 1, 2, 3 and 6.
Results
The test item was not soluble in any of the five recommended vehicles, consequently, an homogenous suspension, obtained in acetone/olive oil (4/1, v/v), was used for the treatment.
The maximum practicable concentration in this vehicle was 50%. Consequently, the concentrations selected for the first preliminary test were 10, 25, 50 and 100%.
Since the test item was irritant at all these concentrations, a complementary preliminary test was undertaken at lower concentrations: 0.5, 1, 2.5 and 5%.
Since the test item was irritant in the complementary preliminary test at the concentrations of 2.5 and 5%, the highest concentration retained for the main test was 1%.
Systemic clinical signs and mortality
No mortality and no clinical signs were observed during the study.
Local irritation
A dryness of the skin of the ears was noted on day 6 in animals given the concentrations of 0.5 and 1%.
Increases in ear thickness were noted at concentrations of 0.5% (19.19% increase) and 1% (30.10% increase).
Proliferation assay
A significant lymphoproliferation was noted in the positive control group given HCA, the study was therefore considered as valid.
A dose-related increase in the SI was recorded and the threshold positive value of 3 was exceeded at 0.5%.
The results are presented in the following table:
Treatment
Concentration (%)
Irritation level
Stimulation Index (SI)
Test item
0.05
non-irritant
1
Test item
0.1
non-irritant
1.88
Test item
0.25
non-irritant
1.67
Test item
0.5
slightly-irritant
5.91
Test item
1
irritant
18.65
HCA
25
-
14.38
In the absence of an excessive local irritation at 0.5% (increase in ear thickness < 30%), the significant lymphoproliferative response observed at this concentration was attributed to delayed contact hypersensitivity.
The EC3value for the test item IMIDAZOLINE 4900 is equal to 0.3%.
Conclusion
Under our experimental conditions, the test item IMIDAZOLINE 4900 (batch No. pilote du 27/07/06) induced delayed contact hypersensitivity in the murine Local Lymph Node Assay.
According to the EC3 value obtained in this experiment, the test item IMIDAZOLINE 4900 should be considered as a strong sensitizer.
These results lead to classification according to CLP (ATP 2): skin sensitiser Cat.1A (EC 3 ≤ 2%)
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.